Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS
Acumen Pharmaceuticals — FY 2022 Earnings Presentation
6 slides from Acumen Pharmaceuticals's earnings presentation, Mar 27, 2023
Slide 1: FY 2022 Financial Results & Business Update
FY 2022 Financial Results & Business Update March 27, 2023 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and
Slide 3: Agenda
Agenda • FY 2022 Business Update Dan O’Connell, Chief Executive Officer • ACU193 Clinical Trial Update Dr. Eric Siemers, Chief Medical Officer • FY 2022 Financial Results Matt Zuga, Chief Business Officer & Chief Financial Officer 3
Slide 4: INTERCEPT-AD Trial Update
INTERCEPT-AD Trial Update • INTERCEPT-AD: Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease (AD) (RCT) → Enrollment completed in February 2023 → Topline results, safety and clinical proof-of-mechanism following full database lock expected in Q3 2023 → Cohort 7 dose level am
Slide 5: INTERCEPT-AD Phase 1 Topline Results Expected in Q3 2023
INTERCEPT-AD Phase 1 Topline Results Expected in Q3 2023 • Phase 1 is a randomized placebo controlled first-in-human, SAD/MAD study with 65 patients enrolled with early Alzheimer’s Disease. → Objectives of the trial are to evaluate safety and tolerability, evaluate PK, and establish target engagemen
Slide 6: Acumen is Well Capitalized, With Expected Cash Runway Through 2025
Acumen is Well Capitalized, With Expected Cash Runway Through 2025 STATUS/ MILESTONES EXPECTED TIMING ~$193M Initiated Ph1 clinical trial INTERCEPT-AD ✓ Cash, cash equivalents and marketable securities as of INTERCEPT-AD enrollment complete ✓ December 31, 2022 Proof-of-mechanism topline results Q3 2
Acumen Pharmaceuticals — FY 2022 Earnings Presentation on 6ix